南财智讯7月29日电,恒瑞医药公告,其子公司山东盛迪医药有限公司收到国家药品监督管理局关于HRS-1893片的《药物临床试验批准通知书》。HRS-1893片为高选择性心肌肌球蛋白小分子抑制剂,拟用于治疗射血分数保留的心力衰竭。该项目累计研发投入约为6,067万元。尽管获得临床试验批准,但药物从临床试验到最终上市仍面临多个不确定因素和风险。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.